ALK tyrosine kinase domain mutations account for 8–10% of diagnosed NB at three hot spots accounting for 85% of mutations: R1275 (43%), F1174 (30%), and F1245 (12%) and 13 minor sites, and correlated significantly with poorer survival in high- and intermediate-risk NB [3–8]. This evidence concerns the gene ALK and neuroblastoma.